Skip header and navigation

Refine By

30 records – page 1 of 3.

ABO blood groups and risk of venous thromboembolism during pregnancy and the puerperium. A population-based, nested case-control study.

https://arctichealth.org/en/permalink/ahliterature29941
Source
J Thromb Haemost. 2005 Feb;3(2):300-4
Publication Type
Article
Date
Feb-2005
Author
T B Larsen
S P Johnsen
M. Gislum
C A I Møller
H. Larsen
H T Sørensen
Author Affiliation
Department of Clinical Biochemistry and Genetics, Odense University Hospital, Sdr. Boulevard 29, DK-5000 Odense, Denmark. tblarsen@dadlnet.dk
Source
J Thromb Haemost. 2005 Feb;3(2):300-4
Date
Feb-2005
Language
English
Publication Type
Article
Keywords
ABO Blood-Group System - physiology
Adult
Case-Control Studies
Female
Humans
Odds Ratio
Postpartum Period - blood
Predictive value of tests
Pregnancy
Pregnancy Complications, Cardiovascular - blood - epidemiology - etiology
Research Support, Non-U.S. Gov't
Risk assessment
Thromboembolism - blood - epidemiology - etiology
Venous Thrombosis - blood - epidemiology - etiology
Abstract
OBJECTIVES: To examine possible associations of ABO blood types with the risk of venous thromboembolism (VTE) in pregnancy and the puerperium. PATIENTS AND METHODS: We conducted a nested case-control study within a cohort of 71,729 women who gave birth to 126,783 children in the North Jutland County, Denmark, from 1980 to 2001. We identified 129 cases with VTE in pregnancy (n = 61) or the puerperium (n = 68), and 258 controls with no VTE. We collected information on ABO blood groups and possible maternal confounding factors and estimated the relative risk [odds ratio (OR)]. RESULTS: Women with an A or AB blood group had elevated risk estimates of VTE in pregnancy or the puerperium compared with women with a O blood group [adjusted ORs 2.4, 95% confidence interval (CI) 1.3, 4.3, and 2.0, 95% CI 0.7, 5.8, respectively]. No increased risk estimate was found for group B (adjusted OR 1.2, 95% CI 0.5, 3.0). The increased risk estimates of VTE for blood groups A and AB appeared present in both pregnancy (adjusted ORs of 3.9, 95% CI 1.5, 9.7, and 2.2, 95% CI 0.4, 12.5) and in the puerperium (adjusted ORs of 2.4, 95% CI 1.0, 4.9 and 2.7, 95% CI 0.8, 9.3). Furthermore, blood groups A and AB appeared to be associated with increased risk estimates for both DVT and pulmonary embolism. CONCLUSION: Keeping the modest statistical precision of our study in mind, blood groups A and AB may be associated with increased risk estimates for VTE in pregnancy and the puerperium.
PubMed ID
15670036 View in PubMed
Less detail

Age- and gender-related differences in the use of secondary medical prevention after primary vascular surgery: a nationwide follow-up study.

https://arctichealth.org/en/permalink/ahliterature127996
Source
Eur J Vasc Endovasc Surg. 2012 Mar;43(3):300-7
Publication Type
Article
Date
Mar-2012
Author
A. Høgh
J S Lindholt
H. Nielsen
L P Jensen
S P Johnsen
Author Affiliation
Department of Vascular Surgery, Regionshospitalet Viborg, Denmark. a_l_hogh@yahoo.dk
Source
Eur J Vasc Endovasc Surg. 2012 Mar;43(3):300-7
Date
Mar-2012
Language
English
Publication Type
Article
Keywords
Adult
Age Distribution
Age Factors
Aged
Aged, 80 and over
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Antihypertensive Agents - therapeutic use
Atherosclerosis - epidemiology - surgery
Calcium Channel Blockers - therapeutic use
Comorbidity
Denmark - epidemiology
Diuretics - therapeutic use
Female
Follow-Up Studies
Humans
Hypolipidemic Agents - therapeutic use
Male
Middle Aged
Peripheral Arterial Disease - epidemiology - prevention & control
Platelet Aggregation Inhibitors - therapeutic use
Practice Guidelines as Topic
Registries
Retrospective Studies
Secondary Prevention - statistics & numerical data
Sex Distribution
Sex Factors
Vascular Surgical Procedures - utilization
Abstract
This study examined the possible age- and gender-related differences in the use of secondary medical prevention following primary vascular reconstruction in a population-based long-term follow-up study.
Using information from nationwide Danish registers, we identified all patients undergoing primary vascular reconstruction in-between 1996 and 2006 (n = 20,761). Data were obtained on all filled prescriptions 6 months and 3, 5 and 10 years after primary vascular reconstruction. Comparisons were made across age and gender groups, using men 40-60 years old as a reference.
Compared to current guidelines the overall use of secondary medical prevention was moderate to low (e.g., lipid-lowering drugs 49.5%, angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists (ACE/ATII) 43.4%, combination of lipid-lowering drugs and anti-platelet therapy and any anti-hypertensive therapy 44.7%). A decline was observed between 6 months and 3 years after surgery. Patients >80 years old were less likely to be prescribed lipid-lowering drugs and combination therapy (e.g.: adjusted risk ratio (RR) 5 years after surgery for men and women 0.63 (95% confidence interval (CI): 0.39-1.02) and 0.48 (95%CI: 0.31-0.75), respectively, whereas smaller and statistical non-significant gender-related differences were observed. The age- and gender-related differences appeared eliminated or substantially reduced in the latest part of the study period (2001-2007).
We found moderate to low use of secondary medical prevention in Denmark compared with recommendations from clinical guidelines. However, the use has increased in recent years and age- and gender-related differences have been reduced or even eliminated.
PubMed ID
22244910 View in PubMed
Less detail

Atrial fibrillation or flutter and stroke: a Danish population-based study of the effectiveness of oral anticoagulation in clinical practice.

https://arctichealth.org/en/permalink/ahliterature47529
Source
J Intern Med. 2002 Jul;252(1):64-9
Publication Type
Article
Date
Jul-2002
Author
L. Frost
S P Johnsen
L. Pedersen
E. Toft
S. Husted
H T Sørensen
Author Affiliation
Department of Clinical Epidemiology, Aarhus University Hospital and Aalborg Sygehus, Denmark. lars.frost@aas.auh.dk
Source
J Intern Med. 2002 Jul;252(1):64-9
Date
Jul-2002
Language
English
Publication Type
Article
Keywords
Administration, Oral
Aged
Aged, 80 and over
Anticoagulants - therapeutic use
Atrial Fibrillation - drug therapy
Atrial Flutter - drug therapy
Cerebrovascular Accident - epidemiology - prevention & control
Cohort Studies
Comorbidity
Denmark - epidemiology
Female
Humans
Incidence
Male
Middle Aged
Randomized Controlled Trials
Registries
Regression Analysis
Research Support, Non-U.S. Gov't
Abstract
OBJECTIVES: A pooled analysis of randomized trials has shown that oral anticoagulation therapy reduces the risk of ischaemic stroke with 68% in patients with atrial fibrillation. We examined the effectiveness of oral anticoagulation on risk of stroke of any nature (fatal and nonfatal ischaemic and/or haemorrhagic stroke) in patients with nonvalvular atrial fibrillation or flutter living in the County of North Jutland, Denmark. DESIGN: Cohort study. SUBJECTS AND METHODS: We used the Hospital Discharge Registry covering the county (490 000 inhabitants) from 1991 to 1998 to identify 2699 men and 2425 women with atrial fibrillation or flutter, aged 60-89 years. Data on prescriptions of anticoagulation were obtained from the National Health Service. We defined use of oral anticoagulation as date of prescription or reiteration plus 90 days. Patients were followed in the County Hospital Discharge Registry until a diagnosis of stroke (fatal and nonfatal ischaemic and/or haemorrhagic stroke), emigration, death or the end of 1998. We used Cox regression analyses to estimate the relative risk of stroke associated with use of oral anticoagulation compared with no use, adjusted for age, diabetes and underlying cardiovascular diseases. RESULTS: Eight hundred and thirty-eight of 2699 men (31%) and 552 of 2425 women (23%) with atrial fibrillation had one or more recorded prescriptions of oral anticoagulation. The incidence rates of stroke were 31 per 1000 person-years of follow-up in men, and 30 per 1000 person-years of follow-up in women. The adjusted relative risks of stroke during anticoagulation were 0.6 [95% confidence interval (CI) 0.4-1.0] in men, and 1.0 (95% CI 0.7-1.6) in women compared with nonuse periods. CONCLUSIONS: The effectiveness of oral anticoagulation in clinical practice may be lesser than the efficacy of oral anticoagulation reported from randomized trials.
Notes
Comment In: J Intern Med. 2003 Jan;253(1):92-312588541
PubMed ID
12074740 View in PubMed
Less detail

Beta-blocker use and clinical outcomes after primary vascular surgery: a nationwide propensity score-matched study.

https://arctichealth.org/en/permalink/ahliterature114026
Source
Eur J Vasc Endovasc Surg. 2013 Jul;46(1):93-102
Publication Type
Article
Date
Jul-2013
Author
A. Høgh
J S Lindholt
H. Nielsen
L P Jensen
S P Johnsen
Author Affiliation
Department of Vascular Surgery, Cardiovascular Research Unit, Viborg Regional Hospital, Denmark. Annette.hoegh@viborg.rm.dk
Source
Eur J Vasc Endovasc Surg. 2013 Jul;46(1):93-102
Date
Jul-2013
Language
English
Publication Type
Article
Keywords
Adrenergic beta-Antagonists - therapeutic use
Adult
Aged
Aged, 80 and over
Denmark
Female
Humans
Male
Middle Aged
Peripheral Arterial Disease - surgery
Postoperative Complications - epidemiology
Propensity Score
Prospective Studies
Treatment Outcome
Vascular Surgical Procedures
Abstract
To explore the associations between beta-blocker use and clinical outcomes (death, hospitalisation with myocardial infarction (MI) or stroke, major amputation and recurrent vascular surgery) after primary vascular reconstruction.
Patients who had primary vascular surgical or endovascular reconstruction due to symptomatic peripheral arterial disease, in Denmark between 1996 and 2007 were included. We obtained data on filled prescriptions, clinical outcomes and confounding factors from population-based healthcare registries. Beta-blocker users were matched to non-users by propensity score, and Cox-regression was performed. All medications were included as time-dependent variables.
We studied 16,945 matched patients (7828 beta-blocker users and 9117 non-users) with a median follow-up period of 582 days (range, 30-4379 days). The cumulative risks were as follows: all-cause mortality, 17.9%; MI, 5.3%; stroke, 5.6%; major amputation, 9.1%; and recurrent vascular surgery, 23.1%. When comparing beta-blocker users with non-users: adjusted hazard ratio: MI, 1.52 (95% CI, 1.31-1.78); stroke, 1.21 (95% CI, 1.03-1.43); and major amputation, 0.80 (95% CI, 0.70-0.93).
Beta-blocker use after primary vascular surgery was associated with a lower risk of major amputation but an increased risk of hospitalisation with MI and stroke. No associations were found between beta-blocker use and all-cause mortality or the risk of recurrent vascular surgery. However, our results are not sufficient to alter the indication for beta-blocker use among symptomatic peripheral arterial disease patients.
PubMed ID
23660119 View in PubMed
Less detail

Birth outcomes in pregnant women treated with low-molecular-weight heparin.

https://arctichealth.org/en/permalink/ahliterature63913
Source
Acta Obstet Gynecol Scand. 2000 Aug;79(8):655-9
Publication Type
Article
Date
Aug-2000
Author
H T Sørensen
S P Johnsen
H. Larsen
L. Pedersen
G L Nielsen
M. Møller
Author Affiliation
The Danish Epidemiology Science Center at the Department of Medicine V, Aarhus University Hospital.
Source
Acta Obstet Gynecol Scand. 2000 Aug;79(8):655-9
Date
Aug-2000
Language
English
Publication Type
Article
Keywords
Abnormalities, Drug-Induced
Adolescent
Adult
Anticoagulants - adverse effects - therapeutic use
Cohort Studies
Female
Heparin, Low-Molecular-Weight - adverse effects - therapeutic use
Humans
Middle Aged
Obstetric labor, premature
Pregnancy
Pregnancy Complications - prevention & control
Pregnancy outcome
Research Support, Non-U.S. Gov't
Venous Thrombosis - prevention & control
Abstract
BACKGROUND: Pregnancy and puerperium are associated with an increased risk of venous thromboembolism. Low-molecular-weight heparin is the anticoagulant of choice in pregnant women because, unlike warfarin, it does not cross the placenta. However, there are limited data on the risk of adverse birth outcomes following use of low-molecular-weight heparin in pregnancy. PATIENTS AND METHODS: We performed a population-based cohort study to examine the safety of low-molecular-weight heparin use in pregnancy using data from the Pharmacoepidemiological Prescription Database, The Danish Medical Birth Registry and the Regional Hospital Discharge Registry in North Jutland County, Denmark. The birth outcomes in a cohort of 66 pregnant women treated with low-molecular-weight heparin between 1991-98 were compared with the birth outcomes of 17,259 pregnant women who did not receive any prescriptive drugs during pregnancy. RESULTS: No increased risk of malformations, low birth weight or stillbirth was found. However, an increased risk of pre-term delivery was found (odds ratio: 2.11, 95%, confidence interval: 0.96-4.65), which could reflect inherited thrombophilia as an indication of low-molecular-weight heparin. CONCLUSION: We have provided additional evidence of the safety of low-molecular-weight heparin use in pregnancy.
PubMed ID
10949230 View in PubMed
Less detail

A cohort study of antihypertensive treatments and risk of renal cell cancer.

https://arctichealth.org/en/permalink/ahliterature17097
Source
Br J Cancer. 2005 Apr 11;92(7):1302-6
Publication Type
Article
Date
Apr-11-2005
Author
J P Fryzek
A H Poulsen
S P Johnsen
J K McLaughlin
H T Sørensen
S. Friis
Author Affiliation
International Epidemiology Institute, Rockville, MD 20850, USA. fryzek@aol.com
Source
Br J Cancer. 2005 Apr 11;92(7):1302-6
Date
Apr-11-2005
Language
English
Publication Type
Article
Keywords
Adult
Aged
Antihypertensive Agents - adverse effects - therapeutic use
Carcinoma, Renal Cell - epidemiology - etiology
Cohort Studies
Confounding Factors (Epidemiology)
Denmark - epidemiology
Female
Humans
Hypertension - complications - drug therapy
Kidney Neoplasms - epidemiology - etiology
Male
Middle Aged
Research Support, Non-U.S. Gov't
Risk factors
Abstract
We studied 335,682 county residents, of whom 113,298 had been prescribed antihypertensive treatment (AHT), in the period 1989-2002 in North Jutland County, Denmark to examine the relation between different AHTs and the risk of renal cell carcinoma (RCC). An internal comparison was performed among the different classes of AHT users with users of beta blockers as the reference, in order to address potential confounding and bias. The average follow-up was 10 years (range 0-13). Use of any AHT was associated with RCC (relative rate (RR)=1.6, 95% confidence interval (CI) 1.3-1.9) compared with nonusers in the general population. Specific classes of AHTs were nonsignificantly associated with RCC, but compared with users of beta blockers, the numbers observed were close to expectation. Analyses by duration of follow-up and number of prescriptions revealed no clear trends for any antihypertensive agent and after 5-years of follow-up, the RRs for all classes of AHT decreased. The elevated RRs for RCC among users of AHTs compared with the general population are unlikely to be causal, but rather reflect confounding due to failure to control for pre-existing hypertension, and protopathic bias, due to the presence of hypertension as an early sign of kidney disease.
PubMed ID
15812478 View in PubMed
Less detail

Complications related to blood donation: a population-based study.

https://arctichealth.org/en/permalink/ahliterature160230
Source
Vox Sang. 2008 Feb;94(2):132-7
Publication Type
Article
Date
Feb-2008
Author
B S Sorensen
S P Johnsen
J. Jorgensen
Author Affiliation
Regional Blood Transfusion Centre and Department of Clinical Immunology, Aarhus University Hospital (Skejby), Aarhus, Denmark. betinasamuelsen@yahoo.dk
Source
Vox Sang. 2008 Feb;94(2):132-7
Date
Feb-2008
Language
English
Publication Type
Article
Keywords
Blood Donors - statistics & numerical data
Data Collection
Denmark
Humans
Needlestick Injuries - epidemiology
Syncope, Vasovagal - epidemiology
Abstract
Population-based data on the rate and outcome of complications related to blood donation are sparse.
Data from a survey conducted in 2003 in Aarhus County, Denmark, were used to assess the overall rate of donor complications. Additional nationwide data on moderate and severe donor complications were obtained from the Danish Register of Complications Related to Blood Donation, with records of all moderate and severe donor complications in Denmark occurring during the period 1997-2003.
In the regional survey, we identified 340 complications of any type among 41 274 donations, corresponding to a rate of 824/100,000 donations [95% confidence interval (CI): 741-916]. All complications were either needle injuries or vasovagal reactions. In the nationwide register, a total of 752 moderate and severe complications were recorded among 2,575,264 donations, corresponding to a rate of 29/100,000 donations (95% CI: 27-31). The rates of complications leading to long-term morbidity or disablement (> 5% loss of working capacity) were 5/100,000 donations (95% CI: 4.2-5.9) and 2.3/100,000 donations (95% CI: 1.8-2.9), respectively.
The risk of complications related to blood donation is low. However, attention towards donor complications is warranted, given the non-negligible rate of complications resulting in long-term morbidity and disablement.
PubMed ID
18028259 View in PubMed
Less detail

Early glycaemic control among patients with type 2 diabetes and initial glucose-lowering treatment: a 13-year population-based cohort study.

https://arctichealth.org/en/permalink/ahliterature272056
Source
Diabetes Obes Metab. 2015 Aug;17(8):771-80
Publication Type
Article
Date
Aug-2015
Author
R W Thomsen
L M Baggesen
E. Svensson
L. Pedersen
H. Nørrelund
E S Buhl
C L Haase
S P Johnsen
Source
Diabetes Obes Metab. 2015 Aug;17(8):771-80
Date
Aug-2015
Language
English
Publication Type
Article
Keywords
Aged
Cohort Studies
Databases, Factual
Denmark
Diabetes Mellitus, Type 2 - blood - drug therapy
Drug Therapy, Combination
Early Medical Intervention - statistics & numerical data
Female
Hemoglobin A, Glycosylated - drug effects - metabolism
Humans
Hypoglycemic Agents - administration & dosage
Insulin - administration & dosage
Male
Metformin - administration & dosage
Middle Aged
Prospective Studies
Regression Analysis
Sulfonylurea Compounds - administration & dosage
Treatment Outcome
Abstract
To examine real-life time trends in early glycaemic control in patients with type 2 diabetes between 2000 and 2012.
We used population-based medical databases to ascertain the association between achievement of glycaemic control with initial glucose-lowering treatment in patients with incident type 2 diabetes in Northern Denmark. Success in reaching glycated haemoglobin (HbA1c) goals within 3-6?months was examined using regression analysis.
Of 38?418 patients, 91% started with oral glucose-lowering drugs in monotherapy. Metformin initiation increased from 32% in 2000-2003 to 90% of all patients in 2010-2012. Pretreatment (interquartile range) HbA1c levels decreased from 8.9 (7.6-10.7)% in 2000-2003 to 7.0 (6.5-8.1)% in 2010-2012. More patients achieved an HbA1c target of
PubMed ID
25929277 View in PubMed
Less detail

Enforcing centralization for gastric cancer in Denmark.

https://arctichealth.org/en/permalink/ahliterature99352
Source
Eur J Surg Oncol. 2010 Sep;36 Suppl 1:S50-4
Publication Type
Article
Date
Sep-2010
Author
L S Jensen
H. Nielsen
P B Mortensen
H K Pilegaard
S P Johnsen
Author Affiliation
Department of Surgery, Aarhus University Hospital, Nørrebrogade 44, Aarhus C, Denmark. lonsusje@rm.dk
Source
Eur J Surg Oncol. 2010 Sep;36 Suppl 1:S50-4
Date
Sep-2010
Language
English
Publication Type
Article
Keywords
Centralized Hospital Services
Databases, Factual
Denmark
Gastrectomy
Hospital Mortality
Humans
Practice Guidelines as Topic
Quality of Health Care
Stomach Neoplasms - mortality - surgery
Treatment Outcome
Abstract
BACKGROUND: Population-based data on the early postoperative outcome after surgery for gastric cancer are very sparse. We examined the development in the quality of surgery and early postoperative outcomes in Denmark following centralization of gastric cancer surgery and implementation of national clinical guidelines. METHODS: All patients in Denmark who underwent resection with curative intent for gastric cancer between 1st July 2003 and 31st December 2008 in one of five university hospitals were registered in a national database. Data on surgical quality and mortality were obtained from the database and compared with the results from the period before centralization (1999-2003). RESULTS: A total of 416 patients underwent resection in the study period. The risk of anastomotic leakages for the whole period was 5.0% (95%CI; 3.2-7.7) compared to 6.1% (95%CI; 4.3-8.6) before centralization, whereas the 30-days hospital mortality was 2.4% (95%CI; 1.2-4.4) compared to 8.2% (95%CI; 6.0-10.4) before centralization. In addition, the percentage of patients with at least 15 lymph nodes removed increased during the study period from 19 in 2003 to 76 in 2008. CONCLUSIONS: Centralization of gastric cancer surgery in Denmark and implementation of national clinical guidelines monitored by a national database was associated with improvements in surgical quality and substantially lower in-hospital mortality.
PubMed ID
20598495 View in PubMed
Less detail

Fetal growth and blood pressure in a Danish population aged 31-51 years.

https://arctichealth.org/en/permalink/ahliterature54040
Source
Scand Cardiovasc J. 2000 Aug;34(4):390-5
Publication Type
Article
Date
Aug-2000
Author
H T Sørensen
A M Thulstrup
B. Nørgdård
M. Engberg
K M Madsen
S P Johnsen
J. Olsen
T. Lauritzen
Author Affiliation
Danish Epidemiology Science Centre, Department of Epidemiology and Social Medicine, University of Aarhus. hts@soci.au.dk
Source
Scand Cardiovasc J. 2000 Aug;34(4):390-5
Date
Aug-2000
Language
English
Publication Type
Article
Keywords
Adult
Birth weight
Blood Pressure - physiology
Blood Pressure Determination
Confidence Intervals
Denmark - epidemiology
Embryonic and Fetal Development - physiology
Female
Health Surveys
Humans
Hypertension - epidemiology
Hypotension - epidemiology
Infant, Newborn
Linear Models
Male
Middle Aged
Pregnancy
Reference Values
Research Support, Non-U.S. Gov't
Risk assessment
Sex Distribution
Abstract
During the past decade, studies have shown an inverse association between birth weight and blood pressure and risk of coronary heart disease in adult life. From old public archives we were able to trace the birth records of 545 out of 905 persons (60.2%) aged 31-51 years who participated in the Ebeltoft Health Promotion Project in Denmark. We examined the associations between birth weight, length at birth, Ponderal Index and systolic and diastolic blood pressure. No associations were found for women. For men, the mean systolic blood pressure fell from 131.1 mmHg with a birth weight of less than 3300 g to 129.6 mmHg with a birth weight of more than 4000 g, and for diastolic blood pressure 81.6 mmHg to 80.3 mmHg, respectively. For men, the mean systolic blood pressure fell from 135.7 mm Hg with a birth length of 30-51 cm to 131.6 with a birth length of 55-62 cm, and for diastolic blood pressure 83.0 mmHg to 78.8 mmHg, respectively. The associations may reflect organ programming in fetal life.
PubMed ID
10983673 View in PubMed
Less detail

30 records – page 1 of 3.